STOCKHOLM -- An investigational P2Y12 inhibitor -- elinogrel -- resulted in faster and greater platelet inhibition and similar clinical efficacy compared with clopidogrel (Plavix) among patients undergoing elective percutaneous coronary intervention, according to a phase II study presented here.
